Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06467357 · ClinicalTrials.gov registry record · Phase 3

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

A Phase 3 study of Biliary Tract Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
620
Enrollment target
20
Study locations

NCT06467357 is a Phase 3 study of Biliary Tract Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 620 participants, above the 222-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (179% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06467357, a Phase 3 study of Biliary Tract Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
620 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.

Conditions Studied

Biliary Tract Cancer

Interventions

  • DRUG Cisplatin
  • DRUG Gemcitabine
  • DRUG Trastuzumab deruxtecan
  • DRUG Rilvegostomig
  • DRUG Durvalumab

Study Locations (20)

California

  • Research Site - Fullerton
  • Research Site - La Jolla
  • Research Site - Los Alamitos
  • Research Site - Los Angeles
  • Research Site - Los Angeles
  • Research Site - San Francisco

Florida

  • Research Site - Fort Myers
  • Research Site - Jacksonville
  • Research Site - St. Petersburg
  • Research Site - Tampa
  • Research Site - West Palm Beach

Arizona

  • Research Site - Scottsdale
  • Research Site - Tucson
  • Research Site - Tucson

Illinois

  • Research Site - Chicago
  • Research Site - Niles

Georgia

  • Research Site - Atlanta

Idaho

  • Research Site - Coeur d'Alene

Maryland

  • Research Site - Towson

Massachusetts

  • Research Site - Worcester

Trial Details

FieldValue
Enrollment Target 620 participants
Start Date 2024-08-12
Est. Completion 2029-05-16
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06467357

The ClinicalTrials.gov registry entry for NCT06467357 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 620 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 222-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (179% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Biliary Tract Cancer appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.

NCT06467357 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT06467357 about?

NCT06467357 is a clinical study titled "Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer". The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.

What is the current status of trial NCT06467357?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 620 participants. The study started on 2024-08-12. Estimated completion is 2029-05-16.

What conditions does trial NCT06467357 study?

This clinical trial studies the following conditions: Biliary Tract Cancer.

What interventions are being tested in trial NCT06467357?

The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), Trastuzumab deruxtecan (DRUG), Rilvegostomig (DRUG), Durvalumab (DRUG).

Who is sponsoring clinical trial NCT06467357?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06467357 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Biliary Tract Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Biliary Tract Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.